We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Founded in 2013, DoorDash builds products and services to help businesses innovate ... in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression Syros Pharmaceuticals , a biopharmaceutical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Bring your passport with you when shopping at Citypharma Paris to be eligible for tax-free shopping. Ask for details and ...

Stanley Consultants has used Deltek products for more than 25 years and recently upgraded ... in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression Syros Pharmaceuticals , a ...

Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

Philadelphia, Pennsylvania-- (Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.